Latest Oligodendroglioma Stories
Johns Hopkins Kimmel Cancer Center scientists have completed a comprehensive map of genetic mutations occurring in the second-most common form of brain cancer, oligodendroglioma.
CHICAGO, June 6, 2011 /PRNewswire/ -- Cell Therapeutics, Inc.
Survival rates of wealthier patients and those younger than 70 with glioblastoma, the most common and aggressive malignant brain tumor, have improved since 2000, whereas rates for those living in poorer areas and older than 70 have remained stagnant.
RTOG reports on the largest trial to-date for patients with newly diagnosed glioblastoma demonstrating the importance and feasibility of prospective molecular analysis of tumor tissue although finding that patients received no additional benefit from dose-intensive temozolomide as compared to standard adjuvant temozolomide after combined temozolomide and radiotherapy.
Findings show that damage to surrounding tissue may play role in determining high-grade glioma patients' long-term outcome.
Novocure today announced that the U.S. Food and Drug Administration (FDA) approved the NovoTTF-100A System (NovoTTF) for the treatment of adult patients with glioblastoma multiforme (GBM) brain tumors, following tumor recurrence after receiving chemotherapy.
Mutations in three pathways important for suppressing tumors cooperate to launch glioblastoma, an aggressive brain tumor that strikes children and adults.
Scientists at Duke Cancer Institute have discovered that genetic mutations found in brain tumors can alter tumor metabolism.
Scientists have identified the type of cell that is at the origin of brain tumors known as oligodendrogliomas.
New research shows that loss of a gene called NFKBIA promotes the growth of glioblastoma multiforme, the most common and deadly form of brain cancer, and suggests that therapies that stabilize this gene may improve survival for certain glioblastoma patients.
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).